BCPEM
RGLS

Bain Capital Public Equity Management’s Regulus Therapeutics RGLS Stock Holding History

Bain Capital Public Equity Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-7,500
Closed -$8.49M – 54
2013
Q3 		$8.49M Buy
+7,500
New +$8.85M 0.21% 45

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bain Capital Public Equity Management's RGLS Position: Q4 2013 in Review

Bain Capital Public Equity Management sold out of Regulus Therapeutics (RGLS) in Q4 2013, closing a stake of 7,500 shares — an estimated $8.49M sold.

Bain Capital Public Equity Management first reported a position in RGLS in Q3 2013 and held it in 1 quarter. The position peaked at $8.49M in Q3 2013. 49 funds tracked by Wall St. Rank hold RGLS as of Q4 2013.

  • Bain Capital Public Equity Management reported no remaining Regulus Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Bain Capital Public Equity Management sold 7,500 Regulus Therapeutics shares in Q4 2013, an estimated $8.49M.
  • Bain Capital Public Equity Management first reported a position in Regulus Therapeutics in Q3 2013 and held it in 1 quarter.
  • Bain Capital Public Equity Management's Regulus Therapeutics position peaked at $8.49M in Q3 2013.
  • 49 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2013.

Based on Bain Capital Public Equity Management's 13F filing for Q4 2013, filed 7 Feb 2014.